AIM: To investigate the possible effects of telmisartan and losartan on cardiac function in adriamycin (ADR)-induced heart failure in rats, and to explore the changes in plasma level of angiotensin-(1-7)[Ang-(1-7)] and myocardial expression of angiotensin II type 1/2 receptors (AT(1)R / AT(2)R) and Mas receptor caused by the two drugs. METHODS: Male Sprague-Dawley rats were randomly divided into 4 groups: the control group, ADR-treated heart failure group (ADR-HF), telmisartan plus ADR-treated group (Tel+ADR) and losartan plus ADR-treated group (Los+ADR). ADR was administrated (2.5 mg/kg, ip, 6 times in 2 weeks). The rats in the Tel+ADR and Los+ADR groups were treated orally with telmisartan (10 mg/kg daily po) and losartan (30 mg/kg daily), respectively, for 6 weeks. The plasma level of Ang-(1-7) was determined using ELISA. The mRNA and protein expression of myocardial Mas receptor, AT(1)R and AT(2)R were measured using RT-PCR and Western blotting, respectively. RESULTS: ADR significantly reduced the plasma level of Ang-(1-7) and the expression of myocardial Mas receptor and myocardial AT(2)R, while significantly increased the expression of myocardial AT(1)R. Treatment with telmisartan and losartan effectively increased the plasma level of Ang-(1-7) and suppressed myocardial AT(1)R expression, but did not influence the expression of Mas receptor and AT(2)R. CONCLUSION: The protective effects of telmisartan and losartan in ADR-induced heart failure may be partially due to regulation of circulating Ang-(1-7) and myocardial AT(1)R expression.
AIM: To investigate the possible effects of telmisartan and losartan on cardiac function in adriamycin (ADR)-induced heart failure in rats, and to explore the changes in plasma level of angiotensin-(1-7)[Ang-(1-7)] and myocardial expression of angiotensin II type 1/2 receptors (AT(1)R / AT(2)R) and Mas receptor caused by the two drugs. METHODS: Male Sprague-Dawley rats were randomly divided into 4 groups: the control group, ADR-treated heart failure group (ADR-HF), telmisartan plus ADR-treated group (Tel+ADR) and losartan plus ADR-treated group (Los+ADR). ADR was administrated (2.5 mg/kg, ip, 6 times in 2 weeks). The rats in the Tel+ADR and Los+ADR groups were treated orally with telmisartan (10 mg/kg daily po) and losartan (30 mg/kg daily), respectively, for 6 weeks. The plasma level of Ang-(1-7) was determined using ELISA. The mRNA and protein expression of myocardial Mas receptor, AT(1)R and AT(2)R were measured using RT-PCR and Western blotting, respectively. RESULTS: ADR significantly reduced the plasma level of Ang-(1-7) and the expression of myocardial Mas receptor and myocardial AT(2)R, while significantly increased the expression of myocardial AT(1)R. Treatment with telmisartan and losartan effectively increased the plasma level of Ang-(1-7) and suppressed myocardial AT(1)R expression, but did not influence the expression of Mas receptor and AT(2)R. CONCLUSION: The protective effects of telmisartan and losartan in ADR-induced heart failure may be partially due to regulation of circulating Ang-(1-7) and myocardial AT(1)R expression.
Authors: Ying Tung Sia; Nathalie Lapointe; Thomas G Parker; James N Tsoporis; Christian F Deschepper; Angelino Calderone; A Pourdjabbar; J F Jasmin; J F Sarrazin; Peter Liu; Albert Adam; Jagdish Butany; Jean L Rouleau Journal: Circulation Date: 2002-05-28 Impact factor: 29.690
Authors: Annemarieke E Loot; Anton J M Roks; Robert H Henning; René A Tio; Albert J H Suurmeijer; Frans Boomsma; Wiek H van Gilst Journal: Circulation Date: 2002-04-02 Impact factor: 29.690
Authors: Justin L Grobe; Adam P Mecca; Melissa Lingis; Vinayak Shenoy; Tonya A Bolton; Juline M Machado; Robert C Speth; Mohan K Raizada; Michael J Katovich Journal: Am J Physiol Heart Circ Physiol Date: 2006-11-10 Impact factor: 4.733
Authors: Robson A S Santos; Ana C Simoes e Silva; Christine Maric; Denise M R Silva; Raquel Pillar Machado; Insa de Buhr; Silvia Heringer-Walther; Sergio Veloso B Pinheiro; Myriam Teresa Lopes; Michael Bader; Elizabeth P Mendes; Virgina Soares Lemos; Maria Jose Campagnole-Santos; Heinz-Peter Schultheiss; Robert Speth; Thomas Walther Journal: Proc Natl Acad Sci U S A Date: 2003-06-26 Impact factor: 11.205
Authors: N M Mordwinkin; C J Meeks; S S Jadhav; T Espinoza; N Roda; G S diZerega; S G Louie; K E Rodgers Journal: Endocrinology Date: 2012-03-20 Impact factor: 4.736
Authors: N L Rukavina Mikusic; N M Kouyoumdzian; E Rouvier; M M Gironacci; J E Toblli; B E Fernández; M R Choi Journal: Scientifica (Cairo) Date: 2016-08-22
Authors: Oliver Domenig; Arndt Manzel; Nadja Grobe; Eva Königshausen; Christopher C Kaltenecker; Johannes J Kovarik; Johannes Stegbauer; Susan B Gurley; Dunja van Oyen; Marlies Antlanger; Michael Bader; Daisy Motta-Santos; Robson A Santos; Khalid M Elased; Marcus D Säemann; Ralf A Linker; Marko Poglitsch Journal: Sci Rep Date: 2016-09-21 Impact factor: 4.379
Authors: Nabil E Boutagy; Attila Feher; Daniel Pfau; Zhao Liu; Nicole M Guerrera; Lisa A Freeburg; Sydney J Womack; Abigail C Hoenes; Caroline Zeiss; Lawrence H Young; Francis G Spinale; Albert J Sinusas Journal: JACC CardioOncol Date: 2020-12-22
Authors: Kátia Daniela Silveira; Lívia Corrêa Barroso; Angélica Thomáz Vieira; Daniel Cisalpino; Cristiano Xavier Lima; Michael Bader; Rosa Maria Esteves Arantes; Robson Augusto Souza Dos Santos; Ana Cristina Simões-E-Silva; Mauro Martins Teixeira Journal: PLoS One Date: 2013-06-07 Impact factor: 3.240